Axoltis Pharma Overview
- Founded
-
2003
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.57M
- Investors
-
6
Axoltis Pharma General Information
Description
Operator of a biotechnology company intended to treat patients suffering from traumatic or severe neurological disorders. The company's drugs assist neural repair in order to treat traumatic or severe degenerative disorders of the central nervous system faced with high unmet medical needs, enabling patients the extension of their potential to the treatment of neurodegenerative diseases and improve functional recovery and quality of life.
Contact Information
Website
www.axoltis.com
Formerly Known As
Neuronax
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 15 - 17, Rue du Pré de la Reine
- 63100 Clermont-Ferrand
- France
+33 04 00 00 00 00
Axoltis Pharma Timeline
Axoltis Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 02-Apr-2021 | $3.57M | 000.00 | 000.00 | Completed | Profitable |
| 7. Later Stage VC | 18-Jul-2020 | 00.000 | 00.00 | 000 | Completed | Profitable |
| 6. Later Stage VC | 05-Mar-2019 | 00.00 | 00.000 | 00.000 | Completed | Profitable |
| 5. Later Stage VC | 12-Oct-2017 | 00.000 | 00.000 | 00.00 | Completed | Profitable |
| 4. Later Stage VC | 15-Jun-2016 | 00.000 | 00.000 | 00.00 | Completed | Profitable |
| 3. Later Stage VC (Series A) | 19-Dec-2014 | 00.000 | 00.000 | 00.000 | Completed | Profitable |
| 2. Later Stage VC | 13-Jul-2013 | $620K | $620K | 00.000 | Completed | Profitable |
| 1. Grant | 01-Oct-2012 | $772K | Completed | Profitable |
Axoltis Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Shares D | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Shares C | 16,009 | $5.942279 | $178.27 | $178.27 | 1x | $178.27 | 3.85% | |
| Ordinary | 9,420 | $5.942279 | $237.69 | $237.69 | 1x | $237.69 | 2.27% |
Axoltis Pharma Executive Team (9)
Axoltis Pharma Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Foucauld Pouet | Axoltis Pharma | Board Member | 000 0000 |
| François Miceli | Sofimac Investment Managers | Supervisory Board Member | 000 0000 |
| Gilles Avenard | Axoltis Pharma | Board Member | 000 0000 |
| Isabelle Baillenx | Self | Board Observer | 000 0000 |
| Luca Bolliger Ph.D | Axoltis Pharma | Chief Business Officer & Board Member | 000 0000 |
Axoltis Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Axoltis Pharma Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Angelor | Angel Group | Minority | 000 0000 | 000000 0 | |
| Auvergne Business Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| FaDiese | Venture Capital | Minority | 000 0000 | 000000 0 | |
| JEREMIE Auvergne | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sofimac Investment Managers | Growth/Expansion | Minority | 000 0000 | 000000 0 |